TP53 and FGFR3 mutations were initially thought to be essentially mutually exclusive, with FGFR3 mutations specific to the Ta pathway and TP53 mutations specific to the CIS pathway [10], [11]. The gene discussed is FGFR3; the disease is in situ carcinoma.